Nebivolol Krka (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors, which slows heart rate and reduces the force of contraction, lowering cardiac output. At the same time it stimulates nitric‑oxide release from the endothelium, causing blood‑vessel relaxation and decreasing peripheral resistance, which together help control blood pressure.

The appropriate dose of nebivolol is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments may be required for special populations, and the prescriber will provide individualized instructions.

Safety data for nebivolol during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Nebivolol Krka. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is a β1‑selective blocker with additional nitric‑oxide‑mediated vasodilatory activity, which may result in fewer metabolic side effects compared with non‑selective beta‑blockers. Its dual mechanism can provide effective blood‑pressure control while preserving endothelial function, distinguishing it from many older agents.

Store Nebivolol Krka at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Nebivolol Krka is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water, and patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as angioedema. Patients should be monitored for these events, especially when initiating therapy or adjusting doses.

Nebivolol is contraindicated in individuals with known hypersensitivity to nebivolol or any component of the formulation, in patients with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and in those with uncompensated heart failure or cardiogenic shock.